Contents

Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY)

June 3, 2017

Clinical trial

Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.

Sivaprasad S, Prevost AT, Vasconcelos JC, Riddell A, Murphy C, Kelly J, Bainbridge J, Tudor-Edwards R, Hopkins D, Hykin P.

Lancet. 2017 Jun 3;389(10085):2193-2203.
Full text | Metrics.

Main finding: Patients with proliferative diabetic retinopathy who were treated with intravitreal aflibercept had an improved visual outcome at 1 year compared to PRP.

 

  • Purpose: To evaluate efficacy and safety of intravitreal aflibercept vs PRP in the management of PDR.
  • Study type: Randomized controlled Trial
  • Condition: Proliferative diabetic retinopathy

Participants: ≥18yo, type 1/2 diabetes, proliferative diabetic retinopathy, BCVA ≥ 6/24.

 

n=232

 

Intervention:

 

Group 1: Intravitreal Aflibercept 2mg
Group 2: Panretinal photocoagulation

Aflibercept was non-inferior and superior to PRP in best-corrected visual acuity at 52 weeks. There were no safety concerns.

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2024 - sourceshed